Indivior Shares Hit 52-Week High on Raised FY Revenue Guidance, Swing to 2Q Profit

Dow Jones

Aug 01, 2025

By Natalie Weger

Indivior shares jumped after the pharmaceuticals company raised its full-year revenue guidance and swung to a second-quarter profit.

Shares earlier rose 21% to a fresh 52-week high of $21.01, and were recently trading at $19.47. The stock is now up 57% for the year.

Indivior on Thursday raised its full-year 2025 revenue guidance to between $1.03 billion and $1.08 billion, up from its previous guidance of $955 million to $1.03 billion.

Chief Executive Joe Ciaffoni said the company's Sublocade treatment's net revenue, and its Suboxone film's pricing stability, led the company to raise its guidance.

Indivior swung to a second-quarter profit of $18 million, or 14 cents a share, compared with a loss of $97 million, or 72 cents a share, in the same quarter last year.

Net revenue increased to $302 million, compared with $299 million in last year's comparable quarter. Analysts polled by FactSet expected $241.7 million.

Indivior also raised its outlook for adjusted earnings before interest, taxes, depreciation and amortization to between $275 million and $300 million, up from its previously issued guidance of $220 million to $260 million.

Write to Natalie Weger at natalie.weger@wsj.com

(END) Dow Jones Newswires

July 31, 2025 14:03 ET (18:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2556337853"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556337853\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556337853?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 02:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556337853","market":"hk","top_or_hot":-1,"title":"Indivior Shares Hit 52-Week High on Raised FY Revenue Guidance, Swing to 2Q Profit","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Natalie Weger \n</p>\n<pre>\n \n</pre>\n<p>\n  Indivior shares jumped after the pharmaceuticals company raised its full-year revenue guidance and swung to a second-quarter profit. \n</p>\n<p>\n  Shares earlier rose 21% to a fresh 52-week high of $21.01, and were recently trading at $19.47. The stock is now up 57% for the year. \n</p>\n<p>\n  Indivior on Thursday raised its full-year 2025 revenue guidance to between $1.03 billion and $1.08 billion, up from its previous guidance of $955 million to $1.03 billion. \n</p>\n<p>\n  Chief Executive Joe Ciaffoni said the company's Sublocade treatment's net revenue, and its Suboxone film's pricing stability, led the company to raise its guidance. \n</p>\n<p>\n  Indivior swung to a second-quarter profit of $18 million, or 14 cents a share, compared with a loss of $97 million, or 72 cents a share, in the same quarter last year. \n</p>\n<p>\n  Net revenue increased to $302 million, compared with $299 million in last year's comparable quarter. Analysts polled by FactSet expected $241.7 million. \n</p>\n<p>\n  Indivior also raised its outlook for adjusted earnings before interest, taxes, depreciation and amortization to between $275 million and $300 million, up from its previously issued guidance of $220 million to $260 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Natalie Weger at natalie.weger@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 31, 2025 14:03 ET (18:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Indivior Shares Hit 52-Week High on Raised FY Revenue Guidance, Swing to 2Q Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndivior Shares Hit 52-Week High on Raised FY Revenue Guidance, Swing to 2Q Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-01 02:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Natalie Weger \n</p>\n<pre>\n \n</pre>\n<p>\n  Indivior shares jumped after the pharmaceuticals company raised its full-year revenue guidance and swung to a second-quarter profit. \n</p>\n<p>\n  Shares earlier rose 21% to a fresh 52-week high of $21.01, and were recently trading at $19.47. The stock is now up 57% for the year. \n</p>\n<p>\n  Indivior on Thursday raised its full-year 2025 revenue guidance to between $1.03 billion and $1.08 billion, up from its previous guidance of $955 million to $1.03 billion. \n</p>\n<p>\n  Chief Executive Joe Ciaffoni said the company's Sublocade treatment's net revenue, and its Suboxone film's pricing stability, led the company to raise its guidance. \n</p>\n<p>\n  Indivior swung to a second-quarter profit of $18 million, or 14 cents a share, compared with a loss of $97 million, or 72 cents a share, in the same quarter last year. \n</p>\n<p>\n  Net revenue increased to $302 million, compared with $299 million in last year's comparable quarter. Analysts polled by FactSet expected $241.7 million. \n</p>\n<p>\n  Indivior also raised its outlook for adjusted earnings before interest, taxes, depreciation and amortization to between $275 million and $300 million, up from its previously issued guidance of $220 million to $260 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Natalie Weger at natalie.weger@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 31, 2025 14:03 ET (18:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INDV","symbol_name":"INDIVIOR PLC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2556337853","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556337853","pubTimestamp":1753984980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Indivior shares jumped after the pharmaceuticals company raised its full-year revenue guidance and swung to a second-quarter profit.Shares earlier rose 21% to a fresh 52-week high of $21.01, and were recently trading at $19.47. The stock is now up 57% for the year.Indivior on Thursday raised its full-year 2025 revenue guidance to between $1.03 billion and $1.08 billion, up from its previous guidance of $955 million to $1.03 billion.Chief Executive Joe Ciaffoni said the company's Sublocade treatment's net revenue, and its Suboxone film's pricing stability, led the company to raise its guidance.Indivior swung to a second-quarter profit of $18 million, or 14 cents a share, compared with a loss of $97 million, or 72 cents a share, in the same quarter last year.Net revenue increased to $302 million, compared with $299 million in last year's comparable quarter. Analysts polled by FactSet expected $241.7 million.Indivior also raised its outlook for adjusted earnings before interest, taxes, de","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"INDV":"INDIVIOR PLC"},"translate_title":"Indivior股价因上调财年收入指引而触及52周高点，并转向第二季度利润","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INDV":0.9},"content_text":"By Natalie Weger \n\n\n \n\n\n  Indivior shares jumped after the pharmaceuticals company raised its full-year revenue guidance and swung to a second-quarter profit. \n\n\n  Shares earlier rose 21% to a fresh 52-week high of $21.01, and were recently trading at $19.47. The stock is now up 57% for the year. \n\n\n  Indivior on Thursday raised its full-year 2025 revenue guidance to between $1.03 billion and $1.08 billion, up from its previous guidance of $955 million to $1.03 billion. \n\n\n  Chief Executive Joe Ciaffoni said the company's Sublocade treatment's net revenue, and its Suboxone film's pricing stability, led the company to raise its guidance. \n\n\n  Indivior swung to a second-quarter profit of $18 million, or 14 cents a share, compared with a loss of $97 million, or 72 cents a share, in the same quarter last year. \n\n\n  Net revenue increased to $302 million, compared with $299 million in last year's comparable quarter. Analysts polled by FactSet expected $241.7 million. \n\n\n  Indivior also raised its outlook for adjusted earnings before interest, taxes, depreciation and amortization to between $275 million and $300 million, up from its previously issued guidance of $220 million to $260 million. \n\n\n \n\n\n  Write to Natalie Weger at natalie.weger@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 31, 2025 14:03 ET (18:03 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}